Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NKTR

Nektar Therapeutics

Dec 05 • 04:00PM ET

0.5120

Dollar change -0.0030
Percentage change -0.58	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.55	Insider Own	1.71%	Shs Outstand	188.56M	Perf Week	21.13%
Market Cap	97.67M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	-3.62%	Shs Float	187.51M	Perf Month	-6.91%
Income	-293.67M	PEG	-	EPS next Q	-0.20	Inst Own	75.99%	Short Float / Ratio	4.27% / 4.81	Perf Quarter	-10.65%
Sales	88.26M	P/S	1.11	EPS this Y	27.23%	Inst Trans	-4.40%	Short Interest	8.01M	Perf Half Y	-15.96%
Book/sh	0.84	P/B	0.61	EPS next Y	51.83%	ROA	-48.01%	Target Price	2.75	Perf Year	-83.21%
Cash/sh	1.95	P/C	0.26	EPS next 5Y	-7.30%	ROE	-102.75%	52W Range	0.41 - 3.19	Perf YTD	-77.35%
Dividend	-	P/FCF	-	EPS past 5Y	-25.98%	ROI	-76.24%	52W High	-83.95%	Beta	0.85
Dividend %	-	Quick Ratio	7.37	Sales past 5Y	37.56%	Gross Margin	62.93%	52W Low	24.09%	ATR	0.04
Employees	216	Current Ratio	7.66	Sales Q/Q	2.20%	Oper. Margin	-164.80%	RSI (14)	52.04	Volatility	7.91% 10.12%
Optionable	Yes	Debt/Eq	1.54	EPS Q/Q	23.51%	Profit Margin	-332.73%	Rel Volume	0.39	Prev Close	0.51
Shortable	Yes	LT Debt/Eq	1.42	Earnings	Nov 07 AMC	Payout	-	Avg Volume	1.66M	Price	0.51
Recom	3.00	SMA20	4.22%	SMA50	-0.64%	SMA200	-30.66%	Volume	649,061	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform	$18 → $6
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform	$21
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy	$20
Sep-10-21	Initiated	BofA Securities	Neutral	$18
Jun-28-21	Upgrade	Stifel	Hold → Buy	$22 → $24
May-18-21	Resumed	Goldman	Neutral	$24
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold	$18

Show Previous Ratings

Nov-09-23 08:39AM	Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.00%
Nov-08-23 11:47AM	Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss (Zacks) -8.76%
Nov-07-23 05:28PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-31-23 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
10:02AM	Loading…
Oct-26-23 10:02AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -7.11%
Oct-13-23 08:30AM	Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress (PR Newswire)
Oct-02-23 09:00AM	Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy (PR Newswire)
Sep-27-23 09:00AM	Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Sep-14-23 07:54AM	Nektar (NKTR) Up on Positive New Data From Eczema Study (Zacks)
Sep-13-23 09:00AM	Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Sep-07-23 11:31AM	Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report? (Zacks)
Sep-06-23 06:00PM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th (PR Newswire)
Aug-17-23 07:02PM	RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics (GuruFocus.com) -6.26%
09:25AM	Loading…
Aug-09-23 09:25AM	Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss (Zacks) -8.94%
Aug-08-23 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Nektar: Q2 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
11:08AM	Nektar Therapeutics sues Lilly for breach of contract around skin drug (American City Business Journals)
Aug-07-23 10:23AM	Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment (Reuters) +91.51%
06:30AM	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company (PR Newswire)
Aug-01-23 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Jul-24-23 03:48AM	Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last? (Zacks) -5.69%
Jul-16-23 08:49AM	Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company (Simply Wall St.)
Jun-12-23 06:00PM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
Jun-08-23 12:55PM	Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel (Simply Wall St.)
11:31AM	Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report? (Zacks)
May-10-23 11:28AM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript (Insider Monkey)
09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
06:45PM	Loading…
May-09-23 06:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Nektar: Q1 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
May-08-23 09:29AM	Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More (Zacks) -5.94%
May-04-23 10:00AM	Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline (Zacks)
May-02-23 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-27-23 08:30AM	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development (PR Newswire)
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-17-23 05:00PM	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan (PR Newswire) +6.26%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Apr-13-23 10:59AM	Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio (Zacks) +10.16%
Apr-11-23 08:57AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics (Zacks) +10.53%
Apr-10-23 10:07AM	5 Stocks to Buy as the Drug Industry Rebounds in 2023 (Zacks) +6.57%
Apr-02-23 08:27AM	We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? (Zacks) -12.42%
Mar-29-23 05:44PM	Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 (PR Newswire)
Mar-24-23 12:00PM	Nektar (NKTR) Upgraded to Buy: Here's Why (Zacks)
Mar-22-23 09:35AM	Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR) (Zacks) -9.73%
Mar-14-23 03:43AM	Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Feb-28-23 05:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results (PR Newswire)
Feb-24-23 10:23AM	Why Nektar Therapeutics Stock Is Plunging Today (Benzinga) -49.66%
07:29AM	Boeing stock slips after deliveries of 787s halted; Beyond Meat shares rally after plant-food makers results (MarketWatch)
Feb-23-23 06:20PM	UPDATE 1-Nektar Therapeutics' autoimmune disease drug fails mid-stage study (Reuters)
05:24PM	Nektar stock drops more than 30% after study involving lupus treatment will not go forward (MarketWatch)
04:30PM	Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus (PR Newswire)
Jan-09-23 09:04AM	Concert (CNCE) Moves 19.3% Higher: Will This Strength Last? (Zacks)
Jan-04-23 09:00AM	Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) +6.85%
Dec-12-22 10:05AM	Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Dec-05-22 08:00AM	Nektar Therapeutics to Host Investor & Analyst Event on December 12th (PR Newswire)
Nov-10-22 09:05AM	Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire) +8.66%
07:58AM	Nektar Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-09-22 09:00AM	Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy (PR Newswire) -5.54%
Nov-04-22 12:35PM	Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates (Zacks) +5.90%
Nov-03-22 06:35PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-28-22 10:00AM	ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-22 10:02AM	Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-25-22 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-24-22 07:55AM	Here's Why We're Watching Nektar Therapeutics' (NASDAQ:NKTR) Cash Burn Situation (Simply Wall St.)
Oct-11-22 05:13PM	Why a S.F. biotech and its potential merger partner pulled the plug on talks (American City Business Journals)
Oct-07-22 03:42PM	Longtime S.F. biotech in talks with London company on 'combination' (American City Business Journals)
11:21AM	PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics (Benzinga)
Sep-07-22 01:15AM	Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress (PR Newswire)
Aug-21-22 09:57AM	Nektar Therapeutics (NASDAQ:NKTR shareholders incur further losses as stock declines 11% this week, taking five-year losses to 75% (Simply Wall St.)
Aug-16-22 08:30AM	Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma (PR Newswire)
Aug-05-22 12:11PM	Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates (Zacks) +10.41%
Aug-04-22 06:15PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Nektar Therapeutics Reports Second Quarter 2022 Financial Results (PR Newswire)
Jul-26-22 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets (PR Newswire) +5.91%
Jul-14-22 06:01AM	Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar? (Zacks)
Jul-01-22 06:30AM	Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer (PR Newswire)
May-27-22 08:00AM	After a record-breaking decade, biotech is discovering what hard times feel like (American City Business Journals)
May-16-22 02:09PM	Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-06-22 10:07AM	Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track (Zacks)
May-05-22 05:55PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-04-22 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-28-22 03:02PM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-27-22 12:00PM	Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store? (Zacks)
Apr-26-22 09:19AM	Nektar Therapeutics Will Cut 70% of Its Staff After Trial Failure (Barrons.com) -8.26%
08:53AM	Nektar to reduce workforce by 70% (MarketWatch)
Apr-25-22 06:00PM	Nektar to cut 500 jobs, sublease some Bay Area space after clinical trial failures (American City Business Journals)
05:57PM	Nektar to cut over 500 jobs following cancer drug failure (Reuters)
04:30PM	Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook (PR Newswire)
Apr-22-22 08:30AM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan (PR Newswire)
Apr-20-22 12:54PM	Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More (Zacks)
09:17AM	Analysts Are Downgrading These 10 Pharmaceutical Stocks (Insider Monkey)
Apr-18-22 05:25PM	Billed as $3.6 billion deal to disrupt cancer, collaboration ends with thud (American City Business Journals) -23.05%
11:30AM	Why Nektar Therapeutics Stock Is Crashing Today (Motley Fool)
10:39AM	Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo (MarketWatch)
09:48AM	Nektar Therapeutics Stock Tanks on More Failed Trials of Its Cancer Drug Bempeg (Barrons.com)
09:32AM	Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures (Zacks)

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBIN HOWARD W	President & CEO	Nov 17	Sale	0.49	19,877	9,740	899,922	Nov 20 08:58 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 17	Sale	0.49	9,646	4,727	274,039	Nov 20 09:02 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 17	Sale	0.49	7,179	3,518	243,780	Nov 20 09:00 PM
Curet Myriam	Director	Sep 18	Sale	0.69	4,359	3,008	27,418	Sep 20 08:09 PM
Ajer Jeffrey Robert	Director	Sep 18	Sale	0.69	4,359	3,008	34,153	Sep 20 08:06 PM
ROBIN HOWARD W	President & CEO	Aug 16	Sale	0.78	19,998	15,598	919,799	Aug 17 08:06 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 16	Sale	0.78	9,703	7,568	283,685	Aug 17 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 16	Sale	0.78	7,221	5,632	250,959	Aug 17 08:07 PM
WHITFIELD ROY A	Director	Jun 14	Sale	0.57	30,000	17,100	216,250	Jun 15 06:26 PM
ROBIN HOWARD W	President & CEO	May 16	Sale	0.72	20,361	14,660	939,797	May 17 08:27 PM
Zalevsky Jonathan	Chief R&D Officer	May 16	Sale	0.72	9,791	7,050	293,388	May 17 08:29 PM
Wilson Mark Andrew	Chief Legal Officer	May 16	Sale	0.72	7,543	5,431	257,680	May 17 08:28 PM
ROBIN HOWARD W	President & CEO	Feb 16	Sale	3.00	19,635	58,905	960,158	Feb 17 08:57 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 16	Sale	3.00	10,484	31,452	303,179	Feb 17 09:00 PM
Thomsen Jillian B.	Chief Financial Officer	Feb 16	Sale	3.00	10,267	30,801	313,497	Feb 17 08:58 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 16	Sale	3.00	8,275	24,825	265,223	Feb 17 08:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience